Bacterial vaccine
A vaccine candidate targeting an undisclosed bacterial pathogen is currently being developed by our partner sanofi-aventis. The vaccine candidate has the potential to address an important unmet medical need in the field of infectious diseases.
The vaccine is based on certain bacterial antigens, which have been identified by our proprietary Antigen Identification Program (AIP®). In July 2005, sanofi-aventis exercised its option on exclusive worldwide commercial rights to the identified vaccine antigens.
The vaccine is currently in pre-clinical development.
Partners
- sanofi-aventis